A young success story open to anyone
Just five years after its founding, Cantourage has quickly established itself as a market leader in the European medical cannabis sector, consistently achieving substantial revenue growth year after year. By leveraging its asset-light strategy and cost efficiency, Cantourage achieved break-even in 2023
In preparation for cannabis legalisation in Germany, Cantourage went public in Autumn of 2022 to enable small and institutional investors to be part of a global growth industry. The company is listed on the Frankfurt Stock Exchange under the ticker “HIGH”.
Just five years after its founding, Cantourage has quickly established itself as a market leader in the European medical cannabis sector, consistently achieving substantial revenue growth year after year. By leveraging its asset-light strategy and cost efficiency, Cantourage achieved break-even in 2023
In preparation for cannabis legalisation in Germany, Cantourage went public in Autumn of 2022 to enable small and institutional investors to be part of a global growth industry. The company is listed on the Frankfurt Stock Exchange under the ticker “HIGH”.
So, what does Cantourage do?
Cantourage sources cannabis from around the world, imports it to its European manufacturing hubs to produce pharmaceutical cannabis medicines, and distributes them throughout Europe's fastest growing medical cannabis markets.
Cantourage helps cultivators access Europe’s rapidly expanding medical cannabis markets. So far, Cantourage has signed over 60 long-term contracts with cannabis growers from 18 countries.
Cantourage implemented a revenue-sharing model which allows Cantourage to avoid investing in costly cultivation facilities and long-term purchase commitments, thereby minimising the company's working capital risk.
Cantourage sources cannabis from around the world, imports it to its European manufacturing hubs to produce pharmaceutical cannabis medicines, and distributes them throughout Europe's fastest growing medical cannabis markets.
Cantourage helps cultivators access Europe’s rapidly expanding medical cannabis markets. So far, Cantourage has signed over 60 long-term contracts with cannabis growers from 18 countries.
Cantourage implemented a revenue-sharing model which allows Cantourage to avoid investing in costly cultivation facilities and long-term purchase commitments, thereby minimising the company's working capital risk.
Based at the heart of Europe's cannabis progress
Upon arrival in Germany, Cantourage handles all necessary processes to transform imported cannabis raw material into prescription medicines. For cannabis flowers, these steps include trimming, microbiological load reduction, packaging and labelling, testing, market release, warehousing, and fulfilment. All these processes are carried out at Cantourage’s production facility in Southern Germany, along with its associated laboratories and service providers.
Upon arrival in Germany, Cantourage handles all necessary processes to transform imported cannabis raw material into prescription medicines.
For cannabis flowers, these steps include trimming, microbiological load reduction, packaging and labelling, testing, market release, warehousing, and fulfilment. All these processes are carried out at Cantourage’s production facility in Southern Germany, along with its associated laboratories and service providers.
Since May of 2024, Cantourage has an additional production partner in Portugal to further stabilise the supply chain and security of supply for all of Europe.
Supplying markets as they open
Once manufactured, the products are shipped to pharmacies throughout Cantourage’s home market Germany, as well as, to the UK via its subsidiary Cantourage UK. Additionally, Cantourage distributes products to five more European markets: Austria, Switzerland, Poland, Czech Republic and Denmark.
Once manufactured, the products are shipped to pharmacies throughout Cantourage’s home market Germany, as well as, to the UK via its subsidiary Cantourage UK.
Additionally, Cantourage distributes products to five more European markets: Austria, Switzerland, Poland, Czech Republic and Denmark.
Additionally, Cantourage has sold products to five more European markets: Austria, Switzerland, Poland, Czech Republic and Denmark.
